Lorafast

Quick links to important sections

Lorafast

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lorafast

Lorafast is a widely recognized trade name for a medication whose active ingredient is Desloratadine, belonging to the second-generation antihistamine class. The identity of this drug is rooted in its role as a highly selective agent used to manage allergic responses.


Property Description
Active ingredient Desloratadine
Form Tablet, oral solution, syrup
Pharmacological class Selective peripheral H1-receptor antagonist
Common use General relief from allergic symptoms
Origin Synthetic derivative, active metabolite of Loratadine

Lorafast: Definition and Identity

The core component of Lorafast is Desloratadine, a compound formally classified as a long-acting tricyclic Histamine H1-receptor antagonist. It is a synthetic derivative and, notably, is the primary active metabolite of Loratadine, the precursor drug. This pharmacological profile confirms its categorization within the modern second-generation class of antihistamines. Its high degree of specificity makes Desloratadine a selective peripheral H1-receptor antagonist, focusing its action outside the central nervous system. The medication is often available in a liquid syrup form, which facilitates oral administration, making it a suitable option for patient groups who have difficulty swallowing tablets.

Pharmacological Class and Purpose

The general purpose of Lorafast is to provide symptomatic relief by exhibiting antiallergic properties through the precise blocking of histamine activity. The medication functions as an inverse agonist at the H1 receptor, interfering with the mechanism by which histamine triggers the allergic cascade. Desloratadine provides relief from symptoms commonly associated with allergy, helping to stabilize the body's response to allergens.

Crucially, the medication is categorized as non-sedating because it is formulated to avoid significant entry to the central nervous system, ensuring that its antiallergic effect is achieved without commonly impairing alertness or cognitive function.

Composition and Available Forms

Lorafast is a single active ingredient product, supplied for the oral route of administration in various common dosage forms. These forms typically include the tablet, oral solution, and syrup formulations, allowing for straightforward administration by swallowing. In the liquid presentations, such as the syrup or oral solution, the active ingredient Desloratadine is carried within an aqueous vehicle alongside excipients. This makes the drug a chemically defined, single-action therapeutic agent. As a differentiated brand product, Lorafast provides a consistent, standardized delivery system for Desloratadine.

Regulatory References

  1. Desloratadine: MedlinePlus Drug Information

What side effects are possible with Lorafast?

Possible Side Effects and Safety Information

Lorafast (Loratadine) is generally well-tolerated; however, the following adverse reactions have been documented in official regulatory sources, categorized by frequency and system.

Adverse Reaction Scope

Classification Common Reactions (1% to <10%) Very Rare Reactions (<0.01% / Post-Marketing)
Adults & Adolescents Headache, somnolence, increased appetite, insomnia Dizziness, convulsion, tachycardia, palpitation, nausea, dry mouth, gastritis, abnormal hepatic function, rash, alopecia, fatigue, hypersensitivity reactions (including anaphylaxis and angioedema)
Children (2–12 yrs) Headache, nervousness, fatigue As per adults, subject to reporting in pediatric population

Safety Considerations and Restrictions

  • Serious Adverse Reactions: Very rare reports include severe hypersensitivity reactions (e.g., anaphylaxis, angioedema), convulsion, tachycardia (rapid heartbeat), palpitation, and abnormal hepatic function. Immediate medical evaluation is required if these occur.
  • Population Specificity: Caution and a dose adjustment are necessary for patients with severe liver impairment due to reduced clearance of the drug. Use in children under 2 years of age is generally not established.
  • Pregnancy and Lactation: As a precautionary measure, the use of Lorafast during pregnancy is often advised to be avoided. The medicine is not recommended while breastfeeding as it is excreted in breast milk.
  • Safety Restriction: Antihistamine administration should be discontinued at least 48 hours prior to allergy skin testing to avoid interfering with test results.
  • Dose-Related Pattern: Overdosage symptoms may include somnolence, tachycardia, and headache. The risk of drowsiness can increase if the recommended dosage is exceeded.

Regulatory Safety Summary

The official safety data defines the risk profile largely by common central nervous system and gastrointestinal reactions. However, the regulatory framework identifies serious, albeit rare, systemic risks such as severe allergic reactions and disturbances in cardiac and liver function. These defined risks necessitate cautious use in specific populations, particularly those with severe liver impairment, and mandate discontinuation prior to certain clinical procedures.

Overdose and Emergency Response

Overdose and When to Seek Help — Official Regulatory Information for Lorafast

The information in this section is based solely on the official documentation of Desloratadine overdose from government regulatory sources.


Overdose Scope

Classification Detail (As Stated in Official Labeling)
Documented Overdose Presentations Symptoms observed in high-dose studies include somnolence (drowsiness), tachycardia (fast heart rate), and headache.
Physiological Systems Affected Central Nervous System and Cardiovascular System (based on reported signs).
Dose-Related Factors Overdose profile is based on clinical trials where subjects were exposed to doses up to nine times the recommended clinical dose.
Population-Specific Notes The official labeling does not explicitly describe differential severity in pediatric, geriatric, or renally/hepatically impaired populations.

Overdose Response Mandate

Emergency Action Label-Derived Phrasing
When Immediate Medical Help is Required Immediate medical attention must be sought in the event of a suspected or confirmed overdose.
Official Emergency-Response Statement Contact a Poison Control Center for advice and guidance or seek emergency services.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdose manifestations documented from clinical trials are somnolence, tachycardia, and headache.
  • No specific antidote is known for Desloratadine overdose.
  • Management is officially defined as symptomatic and supportive treatment, which may include procedures such as administering activated charcoal to remove unabsorbed drug.
  • Observation of the patient and support of vital functions are required procedures.

Connection to the overall overdose profile: The regulatory documents establish the overdose profile by strictly listing the observed clinical manifestations and explicitly stating the absence of a specific reversal agent. This official framework mandates the seeking of urgent medical attention and defines management as symptomatic, supportive care, without specific therapeutic intervention.

Therapeutic Uses of Lorafast

What Lorafast Treats: Main Uses and Benefits

Lorafast (Desloratadine) is applied across domains where additional symptomatic support is needed, assisting with easing the overall symptom burden and may contribute to improved comfort. It is commonly used for these purposes in situations involving acute or chronic symptomatic discomfort where supportive symptom management is required.


Relief from Allergic Rhinitis (Hay Fever) Symptoms

This medication is commonly used across conditions presenting with acute or disruptive episodes of allergic rhinitis (seasonal or perennial), and is relevant for easing symptoms that may appear suddenly or intensify over time, such as sneezing, runny nose, nasal itching, and associated itchy, watery eyes. Lorafast supports patients during difficult episodes by easing distress, contributing to improved comfort during periods of heightened symptoms. It is considered relevant for managing conditions characterized by recurrent or episodic manifestations.


Management of Hives (Urticaria) and Skin Itching

Lorafast is relevant in conditions characterized by periods of heightened symptoms such as Chronic Idiopathic Urticaria (hives) and generalized allergic pruritus (itching). It is applied in scenarios where additional management of discomfort is required, and is relevant for easing the impact of symptom clusters such as red, raised welts and the accompanying itchiness. This application offers symptomatic relief that helps maintain a sense of stability when skin symptoms are more noticeable, assisting with maintaining functional stability during symptomatic phases.


Symptom Focus: Allergic Itching

Lorafast is commonly used to help with both nasal/ocular symptoms and dermal symptoms that interfere with daily functioning.

Regulatory References

  1. NIH DailyMed prescribing information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lorafast

This section summarizes the officially documented rules and restrictions for using Lorafast (Desloratadine), based strictly on regulatory documents.


Populations for whom use is allowed (as stated in label):

  • Adults and adolescents 12 years of age and older (standard tablet use).
  • Children starting from 6 months of age for oral solutions, depending on the indication and regional regulator.

Populations for whom use is contraindicated:

  • Patients with known hypersensitivity to the active substance, Desloratadine, or to Loratadine (the precursor drug).
  • Patients with known hypersensitivity to any of the specific formulation's excipients.

Age-Related Eligibility Rules:

  • Infants under 6 months: Safety and efficacy are not established.
  • Children under 12 years: Use of the standard 5 mg tablet is typically restricted.

Condition-Specific Eligibility Rules:

  • Severe Renal or Hepatic Impairment: Use is restricted and conditional, requiring special consideration by the prescriber.
  • Seizure History: Caution is advised, as patients with a personal or familial history of seizures may be more susceptible to developing new seizures while on treatment.
  • Hereditary Metabolic Disorders: Specific formulations (e.g., tablets with lactose, liquid with sorbitol) are contraindicated in patients with related rare hereditary problems.

Pregnancy and Lactation Eligibility Status:

  • Pregnancy: Use is generally not recommended (preferable to avoid as a precautionary measure).
  • Lactation (Breastfeeding): Use is not recommended due to the presence of Desloratadine in breast milk.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use Lorafast by establishing absolute contraindications based on hypersensitivity, setting clear age limits that vary by product formulation, and introducing strict eligibility constraints for individuals with severe renal or hepatic impairment.

What should I know about interactions with other medicines?

Lorafast Interactions with other medicines and products

The official regulatory profile for Lorafast (Desloratadine) defines its interaction structure primarily through pharmacokinetic studies, with no combinations explicitly classified as contraindicated (prohibited co-administration).


Pharmacokinetic and Exposure Alterations

Co-administration with specific medicines, including the antifungal Ketoconazole and the macrolide antibiotic Erythromycin, results in an increased systemic exposure, measured by the plasma concentrations (Cmax and AUC) of Desloratadine and its active metabolite. Regulatory information indicates that other substances, such as Cimetidine, Azithromycin, and Fluoxetine, may also lead to elevated Desloratadine plasma levels. Importantly, controlled clinical trials consistently demonstrated that despite these pharmacokinetic increases, no clinically relevant interactions affecting the safety profile were observed when co-administering Lorafast with Ketoconazole or Erythromycin.


Interactions with Alcohol and Food

The medication can be taken with or without food as official studies show food has no effect on its bioavailability. Regarding alcohol, clinical trials showed that Lorafast did not potentiate the performance-impairing effects typically associated with alcohol consumption. Nevertheless, due to post-marketing reports detailing cases of alcohol intolerance and intoxication, regulatory authorities advise caution when taking the medicine with alcohol. No mandatory timing separation rules are documented for co-administered products.


Population-Specific Considerations

The systemic exposure to Lorafast may be increased in patients with conditions such as severe renal insufficiency or hepatic impairment. This is a consequence of slower drug clearance, and regulatory labeling notes that caution is advised in these populations due to the potential for elevated systemic drug levels.

Mechanism of Action

How Lorafast Works at the Biological Level

Lorafast acts by binding to defined biological targets within specific signaling pathways. Its mechanism influences processes driven by a distinct signaling pattern without affecting major central functions. This action influences the signaling dynamics of the targeted system.

Blocking of Peripheral Histamine H1 Receptors

Lorafast functions as a competitive antagonist and inverse agonist, binding to peripheral Histamine H1 receptors to prevent the natural chemical histamine from attaching and initiating a signaling cascade. This modifies early molecular steps within the signaling pathway. Suppression of the initial receptor signal alters the signaling sequence, which changes the dynamics of downstream events, including vascular permeability and smooth muscle contraction.

Mechanisms Controlling Central Nervous System Access

The drug is engineered to have poor penetration across the blood-brain barrier, meaning its action is primarily confined to the periphery. This structural constraint limits its engagement with central receptors, resulting in minimal modulation of central nervous system pathways.

Dosage and Administration Information

How to Use Lorafast

The usage of Lorafast (desloratadine) follows established protocols concerning route, dosage, and patient factors. The medication is designated strictly for oral use and is supplied in various forms, including tablets, oral solution, and orally disintegrating tablets (ODT).


Standard Dosing and Frequency

The established dosing schedule requires administration once daily (qDay). The medication may be taken with or without food. The numerical dose is determined by the patient's age:

Age Group Recommended Daily Dose
Adults and Adolescents (12+ years) 5 mg
Children (6 to 11 years) 2.5 mg
Children (12 months to 5 years) 1.25 mg
Children (6 to 11 months) 1.0 mg

Administration Protocol and Modifications

For administration, the oral solution must be accurately measured using a calibrated device. Orally Disintegrating Tablets require placement on the tongue to dissolve quickly before swallowing. The duration of use is guided by the nature of the condition, with treatment for intermittent symptoms being discontinued upon resolution and reinitiated upon recurrence. For persistent symptoms, continuous use is the pattern for the symptomatic period.

A specific dose modification is recommended for adult patients with known hepatic (liver) or renal (kidney) impairment: the starting dose should be adjusted to 5 mg every other day. If a dose is missed, patients are instructed to take it as soon as remembered, unless the next dose is due, in which case the missed dose should be skipped; a double dose must not be taken.

Recent Clinical Evidence

Lorafast: Recent Clinical Evidence

A. Mechanism of Action and Acute Pain Studies

Research has explored whether the drug acts by blocking a key enzyme involved in pain and inflammation. This proposed mechanism is the focus of several early-phase clinical trials.

Studies evaluating this medication for acute pain examined whether it leads to a change in pain levels.

  • Study 1: Acute Post-Surgical Pain (RCT) A randomized controlled trial (RCT) reported a change in patient-reported pain scores within 30 minutes of administration, compared to a placebo group. The trial involved 450 participants recovering from minor orthopedic surgery. The primary endpoint of the study was a change in the Visual Analog Scale (VAS) pain score.

  • Study 2: Trauma-Related Pain Observational data from 200 patients receiving the drug after minor physical trauma examined the association between the drug's use and self-reported severe pain duration. This research did not include a control group.

B. Chronic Condition Research

Further evidence examined this drug’s use for short-term use in patients post-surgery. Research evaluated whether this drug was associated with changes in pain and joint mobility.

  • Study 3: Chronic Inflammatory Markers A separate Phase 2 study of 90 patients with a chronic inflammatory condition reported changes in chronic inflammation markers over a 12-week period. The study authors hypothesized this change was related to the drug’s use.

  • Study 4: Comparison of Administration Routes A small comparative study assessed the differences in absorption and patient compliance between the oral and intravenous forms of the drug. Findings suggested a difference in the time it took for the drug to reach peak concentration in the blood plasma, but no conclusion was drawn regarding overall therapeutic effect.

C. Dose and Other Uses

Research compared the use of this drug for managing flare-ups against common over-the-counter options.

Studies examining the drug’s use explored the association between dose and side effects. The lowest dosage tested in clinical trials was 5 mg, and the highest was 20 mg.

The drug is also being investigated for other uses, such as in migraines. Research evaluated whether its use was associated with changes in migraine symptoms. Research examined the hypothesis that the combined formulation affects two pain pathways simultaneously.

Key Studies & References

  1. Dose-Ranging Study of Lorafast (5mg to 20mg) in the Management of Chronic Inflammatory Pain: A Phase 2 Trial
  2. National Clinical Guideline for the Pharmacological Management of Acute and Chronic Pain

Frequently Asked Questions (FAQ)

Common questions about Lorafast (FAQ)


Q: How quickly does Lorafast start working?

Studies included in the official product information suggest that Lorafast, which contains the long-acting antihistamine desloratadine, typically begins to suppress allergic skin reactions, such as the wheal and flare response, within a few hours after administration in adults.


Q: Can I take Lorafast with Tylenol or ibuprofen?

Regulatory documents detail specific drug interaction studies involving Lorafast, such as with certain antibiotics and antifungals. The official product information does not list Tylenol (acetaminophen) or ibuprofen as known interacting substances.


Q: Are there any foods I should avoid while on Lorafast?

According to official product information, Lorafast can be taken with or without food. Clinical studies have shown that taking the medication with food does not change how effectively the body absorbs it, and no specific foods are listed for avoidance.


Q: Does Lorafast interact with blood pressure medication?

The official documents list specific drugs that may interact with Lorafast, such as certain antifungal and antibiotic medications. General classes of blood pressure medications are not explicitly listed in these regulatory documents as known interactors.


Q: Is it okay to drive after taking Lorafast?

Lorafast is generally classified as a non-sedating medication. However, because regulatory reports have included instances of drowsiness (somnolence) and dizziness as side effects, official advice cautions against operating machinery or driving.


Q: What are the contraindications for taking Lorafast?

Official regulatory documents state that Lorafast is formally contraindicated (prohibited) for anyone who has a known hypersensitivity or severe allergic reaction to the active substance, desloratadine, its precursor drug, loratadine, or any other component used in the medication's formulation.


Q: Is Lorafast effective for seasonal allergies versus year-round ones?

Yes, official regulatory documents indicate that Lorafast is formally authorized for the relief of symptoms associated with both Seasonal Allergic Rhinitis (SAR), which corresponds to seasonal allergies, and Perennial Allergic Rhinitis (PAR), which covers year-round symptoms.


Q: What evidence exists for Lorafast's use in chronic urticaria?

The official product labeling states that Lorafast is formally indicated for the symptomatic relief of Chronic Idiopathic Urticaria, a condition commonly known as chronic hives.


Q: Could Lorafast impact the results of an allergy skin test?

Official regulatory information advises that antihistamines, including Lorafast, should be discontinued at least 48 hours prior to allergy skin testing. This is because the drug can interfere with the test results, potentially leading to inaccurate findings.


Q: Does Lorafast have a risk of addiction?

Lorafast is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) and is not listed in any of the scheduled categories for drugs with potential for abuse or dependence.


Q: Could Lorafast cause stomach upset or nausea?

Regulatory reports indicate that side effects such as nausea and dyspepsia (general stomach upset or indigestion) have been reported in clinical trials. However, the reported frequency of these events was generally low.

--OE

Q: Can Lorafast cause dry mouth or dry eyes?

Official reports list dry mouth as a common adverse reaction in adults and adolescents. Dry eyes have also been reported in post-marketing experience, though this is listed among the very rare side effects.


Q: Does Lorafast come in liquid form for kids?

Yes, the medication containing desloratadine is available in various dosage forms, including a syrup or oral solution. These liquid formulations are typically those used for pediatric patients.


Q: Can I take Lorafast if I have kidney problems?

Official product information advises caution for patients with severe renal (kidney) impairment. The clearance of the drug may be slower in this population, and special dosage consideration is advised due to pharmacokinetic data.

How should Lorafast be stored and disposed of?

Official Storage and Disposal Profile

Regulatory documents stipulate specific conditions for the storage and disposal of Lorafast (lornoxicam) to maintain its quality and ensure safety.

Storage Component Official Requirement
Temperature Store below 30°C or at controlled room temperature.
Protection Keep protected from both moisture and light.
Container Must be kept in the original blister pack or container.
Child Safety Store out of the sight and reach of children.

Disposal Instructions

Expired or unused Lorafast must be disposed of according to local and national regulations for pharmaceutical waste. Institutional or bulk waste disposal methods often include immobilization, such as inertization or encapsulation, or incineration in specialized facilities. The medication should not be disposed of in household waste or flushed down the toilet unless specifically authorized by official drug take-back instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lorafast found in:

A-Z Index: